Shingles Vaccine Linked to Reduced Dementia Risk in Large Study
A large-scale study involving more than 500,000 participants has found a notable association between the Shingrix shingles vaccine and reduced dementia risk. Adults who received the vaccine were 24% less likely to be diagnosed with dementia over a four-year follow-up period compared to those who were not vaccinated.
Researchers calculated that approximately one dementia case could potentially be prevented for every 17 people vaccinated, a finding that could carry significant implications for public health strategies targeting cognitive decline in aging populations.
The mechanism behind this potential protective effect remains under investigation. While the study identifies a correlation, it does not establish causation. Scientists are exploring several hypotheses, including whether the vaccine may reduce inflammation or mitigate viral activity that could otherwise contribute to neurodegenerative processes.
This research adds to growing scientific interest in understanding how immune system interventions might influence brain health outcomes. Further studies would be needed to confirm the relationship and clarify whether the observed benefit stems from the vaccine itself or from other factors.